Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00121134 · ClinicalTrials.gov registry record · NA
Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer
A NA study of Breast Cancer, sponsored by Harold J. Burstein, MD, PhD.
- Completed
- Registry status
- NA
- Development phase
- 164
- Enrollment target
- 5
- Study locations
NCT00121134: Completed NA study of Breast Cancer, sponsored by Harold J. Burstein, MD, PhD.
NCT00121134 is a NA study of Breast Cancer that has completed, run by Harold J. Burstein, MD, PhD. The registered enrollment target is 164 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00121134, a NA study of Breast Cancer, has completed, sponsored by Harold J. Burstein, MD, PhD.
- COMPLETED
- Registry status
- NA
- Development phase
- 164 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this research study is to study the effects (good and bad) of bevacizumab alone, bevacizumab with low-dose continuous chemotherapy (called metronomic chemotherapy), or bevacizumab with capecitabine, on you and your cancer. The goals of the study will be to: * Examine the safety of these drugs * See how easy or difficult it is to be treated with them * Monitor for any signs of recurrent cancer * Look at blood markers that might indicate how the treatment is working
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Bevacizumab
- DRUG Capecitabine
- DRUG Methotrexate
Study Locations (5)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
California
- University of California, San Francisco - San Francisco
Indiana
- Indiana University Cancer Center - Indianapolis
North Carolina
- University of North Carolina - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2005-06 |
| Est. Completion | 2011-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00121134
The ClinicalTrials.gov registry entry for NCT00121134 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Harold J. Burstein, MD, PhD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT00121134 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, California, Indiana.
Frequently Asked Questions
What is clinical trial NCT00121134 about?
NCT00121134 is a clinical study titled "Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer". The purpose of this research study is to study the effects (good and bad) of bevacizumab alone, bevacizumab with low-dose continuous chemotherapy (called metronomic chemotherapy), or bevacizumab with capecitabine, on you and your cancer. The goals of the study will be to: * Examine the safety of th...
What is the current status of trial NCT00121134?
This trial is currently completed. It is a NA study. The enrollment target is 164 participants. The study started on 2005-06. Estimated completion is 2011-05.
What conditions does trial NCT00121134 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00121134?
The interventions under investigation include: Cyclophosphamide (DRUG), Bevacizumab (DRUG), Capecitabine (DRUG), Methotrexate (DRUG).
Who is sponsoring clinical trial NCT00121134?
This trial is sponsored by Harold J. Burstein, MD, PhD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00121134 being conducted?
This trial has 5 study locations across California, Indiana, Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.